Pathogenesis and Treatment in IgA Nephropathy

An International Comparison

  • Yasuhiko Tomino

Table of contents

  1. Front Matter
    Pages i-xi
  2. Pathogenesis

    1. Front Matter
      Pages 1-1
    2. Chee Kay Cheung, Jonathan Barratt
      Pages 3-17
    3. Hong Zhang, Riccardo Magistroni, Ali Gharavi
      Pages 19-42
    4. Ichiei Narita, Yoshikatsu Kaneko, Yumi Itoh, Yuichi Sakamaki, Seitaro Iguchi, Suguru Yamamoto et al.
      Pages 43-51
    5. Jan Novak, Kazuo Takahashi, Hitoshi Suzuki, Colin Reily, Tyler Stewart, Hiroyuki Ueda et al.
      Pages 53-68
    6. Isao Ohsawa
      Pages 97-114
  3. Treatment

    1. Front Matter
      Pages 115-115
    2. Ritsuko Katafuchi
      Pages 167-207
    3. Jukka Mustonen, Kati Kaartinen, Jaana Syrjänen, Ilkka Pörsti
      Pages 221-240
    4. Kazuo Takahashi, Ryohei Yamamoto, Yukio Yuzawa
      Pages 251-262
    5. Ryohei Yamamoto
      Pages 263-301
    6. Kyoko Watanabe, Keita Hirano
      Pages 303-309
    7. Takashi Yasuda, Yoshinari Yasuda, Sachiko Ohde, Osamu Takahashi, Tetsuya Kawamura, Seiichi Matsuo
      Pages 331-338
  4. Back Matter
    Pages 339-342

About this book


This book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe, and the United States. More than 40 years have passed since Dr. Jean Berger first described primary IgA nephropathy (“Nephropathy with mesangial IgA-IgG deposits”) as a new disease entity.

Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (IgA1) and C3 in the glomerular mesangial areas with mesangial cell proliferation and the expansion of mesangial matrices. It is clear that IgA nephropathy is one of the most common types of chronic glomerulonephritis in the world. This disease may lead to end-stage kidney disease, with its enormous economic impact on healthcare everywhere. Efforts by many investigators around the world have gradually clarified various aspects of the pathogenesis and treatment of IgA nephropathy. However, there are many controversial strategies for the treatment of patients with IgA nephropathy throughout the world, as there are several limitations for treatment in each country. This volume provides nephrologists everywhere with an overview and comparison of both global and regional findings in basic and clinical fields in IgA nephropathy. It covers genetic variation, aberrant IgA1 production, and classification etiology, guidelines, and treatment goals, with all chapters written by top international researchers.


GdIgA1 IgA Nephropathy IgA1 production KDIGO guideline chronic glomerulonephritis mesangial cell mucosal immunity steroid pulse therapy

Editors and affiliations

  • Yasuhiko Tomino
    • 1
  1. 1.Tokyo 113-8421Japan

Bibliographic information